NCT-501

NCT-501 is a reversible, non-competitive, selective, blood-brain barrier-permeable ALDH1A1 inhibitor with an IC₅₀ of 40 nM. NCT-501 inhibits the AKT-β-catenin signaling pathway, induces necroptosis in nasopharyngeal carcinoma cells, suppresses their proliferation and inhibits stem cell spheroid formation. NCT-501 can be used in research related to nasopharyngeal carcinoma, esophageal squamous cell carcinoma and malignant tumors^[1][2][3]. IC50 & Target:IC50: 40 nM (hALDH1A1)^[2] In Vitro:NCT-501 inhibits stem cell spheroid formation in human nasopharyngeal carcinoma SUNE1 cells^[1].
NCT-501 (5 days) reduces cell viability in human nasopharyngeal carcinoma 5-8F, 6-10B, SUNE1, and HK1 cells with IC₅₀ values of 96.91 μM, 64.15 μM, 27.84 μM, and 67.97 μM respectively, with greater sensitivity in cells with higher ALDH1A1 expression^[1].
NCT-501 (14 days) inhibits colony formation in human nasopharyngeal carcinoma 6-10B and SUNE1 cells^[1].
NCT-501 induces necroptosis in human nasopharyngeal carcinoma SUNE1 cells, as evidenced by caspase-independent cell death, characteristic nuclear and ultrastructural changes, and HMGB1 translocation^[1].
NCT-501 downregulates ALDH1A1 expression and inhibits components of the AKT-β-catenin signaling pathway in TE-1 esophageal squamous cell carcinoma cells, with significant reductions in ALDH1A1 and AKT1 protein levels to ~0.4 relative to β-actin^[2].